Patent Number: 8,877,759

Title: Aminopyrazines as ATR kinase inhibitors

Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: ##STR00001## wherein the variables are as defined herein.

Inventors: Charrier; Jean-Damien (Wantage, GB), Kay; David (Purton, GB), MacCormick; Somhairle (Reading, GB), Storck; Pierre-Henri (Abingdon, GB), Pinder; Joanne (Didcot, GB), O'Donnell; Michael Edward (Abingdon, GB), Knegtel; Ronald Marcellus Alphonsus (Abingdon, GB), Young; Stephen Clinton (Oxford, GB), Reaper; Philip Michael (Shillingford, GB), Durrant; Steven John (Abingdon, GB), Twin; Heather Clare (Wantage, GB), Davis; Christopher John (Salisbury, GB)

Assignee: Vertex Pharnaceuticals Incorporated

International Classification: A61K 31/4965 (20060101); C07D 403/00 (20060101)

Expiration Date: 2019-11-04 0:00:00